BioXcel Therapeutics is trading 5% down in pre-market at $1.13 after reporting a Q2 earnings miss and revenue falling short of estimates. * The company reported a Q2 EPS of $-0.490, missing analyst estimates of $-0.423. * Revenue for the quarter came in at $182K, falling short of the consensus estimate of $403.32K. * This comes amid ongoing financial pressure, including an extended strategic transaction deadline to August 21, 2026, and a $9.0 million payment due August 31, 2026.